Antitumor activity of a combined regimen of capecitabine and bevacizumab in a xenograft model of human breast cancer.

被引：0
|
作者：
Higgins, B. [1 ]
Kolinsky, K. [1 ]
Zhang, Y-E [1 ]
Moisa, C. [1 ]
Dugan, U. [1 ]
Packman, K. [1 ]
机构：
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [1] Antitumor activity of capecitabine in combination with bevacizumab and cyclophosphamide in triple-negative breast cancer xenograft model
    Yanagisawa, Mieko
    Yorozu, Keigo
    Satoh, Fumi
    Kurasawa, Mitsue
    Yamamoto, Kaname
    Fujimoto-Ouchi, Kaori
    CANCER RESEARCH, 2011, 71
  • [2] Preclinical activity of capecitabine (X) and bevacizumab (A) in a breast cancer xenograft model
    Higgins, Brian
    Kolinsky, Kenneth
    Zhang, Yu-E
    Moisa, Carlos
    Dugan, Ute
    Packman, Kathryn
    ANNALS OF ONCOLOGY, 2006, 17 : 58 - 58
  • [3] Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models
    Yanagisawa, Mieko
    Fujimoto-Ouchi, Kaori
    Yorozu, Keigo
    Yamashita, Yoriko
    Mori, Kazushige
    ONCOLOGY REPORTS, 2009, 22 (02) : 241 - 247
  • [4] Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model
    Higgins, Brian
    Kolinsky, Kenneth
    Linn, Michael
    Adames, Violeta
    Zhang, Yu-E
    Moisa, Carlos
    Dugan, Ute
    Heimbrook, David
    Packman, Kathryn
    ANTICANCER RESEARCH, 2007, 27 (4B) : 2279 - 2287
  • [5] In vivo activity of a novel regimen of capecitabine (C) in a breast cancer xenograft model.
    Traina, T. A.
    Theodoulou, M.
    Higgins, B.
    Kolinsky, K.
    Packman, K.
    Dugan, U.
    Hudis, C. A.
    Norton, L.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S279 - S280
  • [6] Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model
    Traina, T. A.
    Higgins, B.
    Theodoulou, M.
    Dugan, U.
    Kolinsky, K.
    Zhang, Y.
    Heimbrook, D.
    Packman, K.
    Hudis, C.
    Norton, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL
    Li, H.
    Takayama, K.
    Wang, S.
    Furuyama, K.
    Harada, T.
    Nakanishi, Y.
    RESPIROLOGY, 2012, 17 : 90 - 90
  • [8] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB IN HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL
    Li, Heyan
    Takayama, Koichi
    Shiraishi, Yoshimasa
    Wang, Shuo
    Furuyama, Kazuto
    Harada, Taishi
    Nakanishi, Yoichi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S462 - S462
  • [9] Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft
    Bandyopadhyay, A
    López-Casillas, F
    Malik, SN
    Montiel, JL
    Mendoza, V
    Yang, JH
    Sun, LZ
    CANCER RESEARCH, 2002, 62 (16) : 4690 - 4695
  • [10] Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models
    Kaori F. -Ouchi
    Mieko Yanagisawa
    Fumiko Sekiguchi
    Yutaka Tanaka
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 693 - 702
12345